Insights

Funding and Growth Indapta Therapeutics secured significant funding ($60 million in Series A) for developing their g-NK cell therapy, showcasing financial stability and growth potential.

Key Personnel Strength With the appointment of Dr. Mark W. Frohlich as Chief Executive Officer, Indapta has brought in experienced leadership to drive strategy, innovation, and market penetration.

FDA Recognition Recognition by the U.S. FDA with the Fast Track designation for IDP-023 positions Indapta at the forefront of advancing therapies for non-hodgkin's lymphoma and myeloma, presenting partnership and collaboration opportunities.

Research Grants and Partnerships Indapta's multiple research grants and collaborations, including $4.5 million from the Cancer Prevention and Research Institute of Texas, create avenues for further research, clinical trials, and potential strategic partnerships.

Market Presence against Competitors Amidst competitors like Allogene Therapeutics and bluebird bio, Indapta's focus on allogeneic natural killer cell therapy sets them apart, opening doors for differentiation and customer interest in innovative treatment solutions.

Indapta Therapeutics Tech Stack

Indapta Therapeutics uses 8 technology products and services including Google Font API, jQuery Migrate, Floating UI, and more. Explore Indapta Therapeutics's tech stack below.

  • Google Font API
    Font Scripts
  • jQuery Migrate
    Javascript Libraries
  • Floating UI
    Miscellaneous
  • Elementor
    Page Builders
  • WP Engine
    Platform As A Service
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines
  • WPForms
    Web Platform Extensions

Media & News

Indapta Therapeutics's Email Address Formats

Indapta Therapeutics uses at least 1 format(s):
Indapta Therapeutics Email FormatsExamplePercentage
FLast@indapta.comJDoe@indapta.com
45%
First@indapta.comJohn@indapta.com
5%
FLast@indapta.comJDoe@indapta.com
45%
First@indapta.comJohn@indapta.com
5%

Frequently Asked Questions

Where is Indapta Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Indapta Therapeutics's main headquarters is located at Seattle & Houston , US. The company has employees across 2 continents, including North AmericaAsia.

What is Indapta Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Indapta Therapeutics's official website is indapta.com and has social profiles on LinkedIn.

How much revenue does Indapta Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2024, Indapta Therapeutics's annual revenue reached $750K.

What is Indapta Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Indapta Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Indapta Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2024, Indapta Therapeutics has approximately 20 employees across 2 continents, including North AmericaAsia. Key team members include Chief Executive Officer: M. F.Chief Operating Officer And Founder: G. D.Chief Scientific Officer: S. M.. Explore Indapta Therapeutics's employee directory with LeadIQ.

What industry does Indapta Therapeutics belong to?

Minus sign iconPlus sign icon
Indapta Therapeutics operates in the Biotechnology Research industry.

What technology does Indapta Therapeutics use?

Minus sign iconPlus sign icon
Indapta Therapeutics's tech stack includes Google Font APIjQuery MigrateFloating UIElementorWP EnginePHPYoast SEOWPForms.

What is Indapta Therapeutics's email format?

Minus sign iconPlus sign icon
Indapta Therapeutics's email format typically follows the pattern of . Find more Indapta Therapeutics email formats with LeadIQ.

How much funding has Indapta Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2024, Indapta Therapeutics has raised $4.5M in funding. The last funding round occurred on May 21, 2024 for $4.5M.
Indapta Therapeutics

Indapta Therapeutics

Biotechnology ResearchSeattle & Houston , United States11-50 Employees

Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.

Section iconCompany Overview

Headquarters
Seattle & Houston , US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $4.5M

    Indapta Therapeutics has raised a total of $4.5M of funding over 7 rounds. Their latest funding round was raised on May 21, 2024 in the amount of $4.5M.

  • $10M

    Indapta Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $4.5M

    Indapta Therapeutics has raised a total of $4.5M of funding over 7 rounds. Their latest funding round was raised on May 21, 2024 in the amount of $4.5M.

  • $10M

    Indapta Therapeutics's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.